SCHEMBL6492875

SCHEMBL6492875

Cc1ccc(CNc2ccc3c(c2)Cc2ccccc2-3)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
KDM4E B2RXH2 5/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
CASP1 P29466 1/20 0.53
HBB P68871 1/20 0.53
DHFR P00374 1/20 0.51
CYP1A2 P05177 2/20 0.47
ADRA2A P08913 1/20 0.47
MAOA P21397 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR2B P41595 1/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493304 0.90 DHFR (0.51) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6482117 0.88 DHFR (0.54) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6482900 0.78 DHFR (0.53) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6483935 0.77 CYP1A2 (0.55) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6495966 0.77 CYP1A2 (0.49) MAPTMEN1KMT2AGAADHFR
SCHEMBL6490390 0.77 CYP1A2 (0.49) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6494134 0.77 MAPT (0.55) MAPTKDM4EMEN1KMT2AGAA
SCHEMBL6483040 0.76 DHFR (0.46) MAPTKDM4EMEN1KMT2ADHFR
SCHEMBL6483232 0.76 MEN1 (0.68) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6495501 0.76 DHFR (0.46) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885KDM4E 1279/4885MEN1 3995/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885KDM4E 1476/4885MEN1 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.